Tratamiento experimental contra cáncer de pulmón eleva supervivencia a 21 meses, según estudio

Outlet: El Economista México · Reuters · Published 24/10/2026 16:53 UTC

Only El Economista México reports this: no contrast yet

None of the other outlets we follow has reported this story, so there are no versions to compare. If others publish it or data appear that test it, it will move to the comparison.

La combinación de Imdelltra e Imfinzi alcanzó una supervivencia mediana de 21.1 meses, frente a 12.7 meses con la inmunoterapia sola, en un estudio de 563 pacientes

Read on the original outlet ↗

Capture record

Source: https://www.eleconomista.com.mx/politica/tratamiento-experimental-cancer-pulmon-eleva-supervivencia-21-meses-estudio-20261024-840301.html
Published: 24/10/2026 16:53 UTC
Captured: 24/10/2026 17:09 UTC
Text fingerprint: 7f55e302a51b3961 · 681 words
Changes detected: 0
Archived copy: Wayback Machine ↗

The fingerprint (sha256) and the capture date prove what the story said when we analysed it, even if it changes later.